Journal
JOURNAL OF VIROLOGY
Volume 75, Issue 15, Pages 6953-6961Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.75.15.6953-6961.2001
Keywords
-
Categories
Funding
- NCRR NIH HHS [M01-RR00425, M01 RR000425] Funding Source: Medline
- NIAID NIH HHS [AI44610] Funding Source: Medline
Ask authors/readers for more resources
The partial control of viremia during acute human immunodeficiency virus type 1 (HIV-1) infection is accompanied by an HIV-1-specific cytotoxic T-lymphocyte (CTL) response and an absent or infrequent neutralizing antibody response. The control of HIV-1 viremia has thus been attributed primarily, if not exclusively, to CTL activity. In this study, the role of antibody in controlling viremia was investigated by measuring the ability of plasma or immunoglobulin G from acutely infected patients to inhibit primary strains of HIV-1 in the presence of natural-killer (NK) effector cells. Antibody that inhibits virus when combined with effector cells was present in the majority of patients within days or weeks after onset of symptoms of acute infection. Furthermore, the magnitude of this effector cell-mediated antiviral antibody response was inversely associated with plasma viremia level, and both autologous and heterologous HIV-1 strains were inhibited. Finally, antibody from acutely infected patients likely reduced HIV-1 yield in vitro both by mediating effector cell lysis of target cells expressing HIV-1 glycoproteins and by augmenting the release of beta -chemokines from NK cells. HIV-1-specific antibody may be an important contributor to the early control of HIV viremia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available